Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | GAA | P10253 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620057 | 0.78 | AADAT (0.35) | AADATTLR9ALDH1A1KDM4EGAA | |
| SCHEMBL9903242 | 0.78 | OPRM1 (0.44) | AADATTLR9ALDH1A1KDM4EGAA | |
| SCHEMBL30722969 | 0.78 | AADAT (0.35) | AADATTLR9ALDH1A1KDM4EGAA | |
| SCHEMBL28878339 | 0.75 | MEN1 (0.46) | ALDH1A1KDM4EGAAPOLBMGLL | |
| SCHEMBL7612610 | 0.70 | CDC25A (0.56) | ALDH1A1KDM4EGAAPOLBATM | |
| SCHEMBL7808629 | 0.69 | AADAT (0.37) | AADATALDH1A1KDM4EGAAHTT | |
| SCHEMBL19410674 | 0.69 | HTR2A (0.45) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL31124667 | 0.62 | MEN1 (0.35) | ALDH1A1KDM4EGAAMEN1KMT2A | |
| SCHEMBL22631177 | 0.60 | AADAT (0.58) | AADATALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL6902840 | 0.59 | MEN1 (0.52) | ALDH1A1KDM4EPOLBHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4885370-A | Synthetic method for indol-2(3H)-ones | PFIZER INC. (US) | 1989-12-05 | — | — | US | claimed |
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2009135000-A2 | INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-117199 AND ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-07-24 | — | — | US | disclosed |
| WO-2007117699-A2 | INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-87877, NSC-117199 AND THEIR ANALOGS | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1751142-A1 | PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7145008-B2 | Selective inhibitors of certain receptor and non-receptor tyrosine kinases such as FAK (focal adhesion kinase); anticancer agents; N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-4-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide for example | PFIZER INC (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2005111022-A1 | PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256125-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC. | 2005-11-17 | — | — | US | disclosed |
| US-4885370-A | Synthetic method for indol-2(3H)-ones | PFIZER INC. (US) | 1989-12-05 | — | — | US | disclosed |
| US-4761485-A | Synthetic method for indol-2(3H)-ones | PFIZER INC. (US) | 1988-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | PTPN7, PTPN1, PTPN2 | AADAT 4747/4885TLR9 3081/4885ALDH1A1 3859/4885 |
| US-20050256125-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | DPYD, TYMP, TYMS | AADAT 1184/4885TLR9 4167/4885ALDH1A1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.